Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. Issue 7 (7th June 2022)

Record Type:: Journal Article
Title:: Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. Issue 7 (7th June 2022)
Main Title:: Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma
Authors:: Barr, Paul M.
Smith, Stephen D.
Roschewski, Mark J.
O'Brien, Susan M.
Sharman, Jeff P.
Melear, Jason M.
Patel, Priti
Calvo, Roser
Yang, Helen
Spurgeon, Stephen E.
Abstract:
Is Part Of:: Leukemia & lymphoma. Volume 63:Issue 7(2022)
Journal:: Leukemia & lymphoma
Issue:: Volume 63:Issue 7(2022)
Issue Display:: Volume 63, Issue 7 (2022)
Year:: 2022
Volume:: 63
Issue:: 7
Issue Sort Value:: 2022-0063-0007-0000
Page Start:: 1728
Page End:: 1732
Publication Date:: 2022-06-07
Subjects:: Leukemia -- Periodicals
Lymphomas -- Periodicals
616.99419
Journal URLs:: http://informahealthcare.com ↗
DOI:: 10.1080/10428194.2022.2043301 ↗
Languages:: English
ISSNs:: 1042-8194
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 5185.251500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 22369.xml